CN Patent

CN113015532B — 包含β-内酰胺酶抑制剂的组合式组合物

Assigned to VenatoRx Pharmaceuticals Inc · Expires 2024-03-15 · 2y expired

What this patent protects

本文描述了包含β‑内酰胺酶抑制剂的组合式组合物。在某些实施方案中，本文所述的组合式组合物在细菌感染的治疗中是有用的。

USPTO Abstract

本文描述了包含β‑内酰胺酶抑制剂的组合式组合物。在某些实施方案中，本文所述的组合式组合物在细菌感染的治疗中是有用的。

Drugs covered by this patent

durlobactam-sodium (DURLOBACTAM SODIUM)

Patent Metadata

Patent number: CN113015532B
Jurisdiction: CN
Classification: —
Expires: 2024-03-15
Drug substance claim: No
Drug product claim: No
Assignee: VenatoRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.